title: [HER-2/neu-testing in breast cancer: is the immunocytochemistry competent?].
abstract: According to ASCO/CAP guidelines, there are two recommended methods for Her2/neu-testing in breast cancer patients such as immunohistochemistry and fluorescence in situ hybridization. This paper analyses results of alternative immunocytochemical method for Her2/neu detection and its diagnostic pitfalls.
authors.forename: A É
authors.initials: AÉ
authors.lastname: Matsionis
authors.forename: I A
authors.initials: IA
authors.lastname: Pavlenko
authors.forename: A V
authors.initials: AV
authors.lastname: Petrov
authors.forename: P E
authors.initials: PE
authors.lastname: Povilaĭtite
mesh_terms: D000818:Animals; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology*; D005260:Female; D007150:Immunohistochemistry / Q000379:methods; D017404:In Situ Hybridization, Fluorescence; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human